Antibody-based therapeutics targeting CD33, CD45, and CD66
RB Walter, OW Press, ID Bernstein - Targeted therapy of acute myeloid …, 2014 - Springer
Targeted therapy of acute myeloid leukemia (AML) with monoclonal antibodies (MoAbs) has
thus far been mostly directed at CD33, CD45, and CD66. The notion that some AMLs may …
thus far been mostly directed at CD33, CD45, and CD66. The notion that some AMLs may …
Investigational CD33-targeted therapeutics for acute myeloid leukemia
RB Walter - Expert opinion on investigational drugs, 2018 - Taylor & Francis
Introduction: There is long-standing interest in drugs targeting the myeloid differentiation
antigen CD33 in acute myeloid leukemia (AML). Positive results from randomized trials with …
antigen CD33 in acute myeloid leukemia (AML). Positive results from randomized trials with …
The past and future of CD33 as therapeutic target in acute myeloid leukemia
GS Laszlo, EH Estey, RB Walter - Blood reviews, 2014 - Elsevier
CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …
The role of CD33 as therapeutic target in acute myeloid leukemia
RB Walter - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
CD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML)
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects
Monoclonal antibodies are a new class of agents targeted at specific receptors on cancer
cells. In addition to direct cellular effects, antibodies can carry substances to the targeted …
cells. In addition to direct cellular effects, antibodies can carry substances to the targeted …
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
RB Walter, FR Appelbaum, EH Estey… - Blood, The Journal of …, 2012 - ashpublications.org
Although the identification of cancer stem cells as therapeutic targets is now actively being
pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia …
pursued in many human malignancies, the leukemic stem cells in acute myeloid leukemia …
What happened to anti-CD33 therapy for acute myeloid leukemia?
JG Jurcic - Current hematologic malignancy reports, 2012 - Springer
Abstract CD33, a 67-kDa glycoprotein expressed on the majority of myeloid leukemia cells
as well as on normal myeloid and monocytic precursors, has been an attractive target for …
as well as on normal myeloid and monocytic precursors, has been an attractive target for …
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger - Leukemia, 2005 - nature.com
CD33 is expressed on the malignant blast cells in most cases of acute myeloid leukemia
(AML) but not on normal hematopoietic pluripotent stem cells. Antibody-based therapies for …
(AML) but not on normal hematopoietic pluripotent stem cells. Antibody-based therapies for …
[HTML][HTML] SGN-CD33A: a novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against …
MSK Sutherland, RB Walter, SC Jeffrey, PJ Burke, C Yu… - Blood, 2012 - Elsevier
Abstract 3589 Outcomes for patients with acute myeloid leukemia (AML) are poor,
highlighting the need for novel treatment options. Most AML cells express the myeloid …
highlighting the need for novel treatment options. Most AML cells express the myeloid …